---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-056026"
form_type: "8-K/A"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2023-10-27T23:59:59+00:00"
generated_at: "2026-06-09T07:11:44.206619+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology files Apexigen audited FY22 results; net loss $32M, cash $14.8M

## Summary
- Apexigen FY22 net loss of $32.1M, revenue $0; R&D expense $23.0M, G&A $9.7M.
- Audited balance sheet at Dec 31, 2022: cash and short-term investments $16.8M, accumulated deficit $176.8M.
- Auditors included going-concern doubt; Apexigen had suffered recurring losses and net capital deficiency.
- The amendment provides pro forma combined financials as of June 30, 2023 and for FY22, giving effect to the August 23, 2023 acquisition.

## SEC filing metadata
- accession: 0000950170-23-056026
- form_type: 8-K/A
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2023-10-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017023056026/0000950170-23-056026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017023056026/pyxs-20230823.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-056026
- JSON: https://secwatch.observer/filing/0000950170-23-056026.json
- Plain text: https://secwatch.observer/filing/0000950170-23-056026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.